UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 18, 2019
AERPIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-38560 | 61-1547850 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
9987 Carver Road Cincinnati, OH |
45242 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code (513) 985-1920
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which | ||
Common stock, $0.0001 par value per share | ARPO | Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07. | Submission of Matters to a Vote of Security Holders. |
On June 18, 2019, Aerpio Pharmaceuticals, Inc. (the Company) held its Annual Meeting of Stockholders (the Annual Meeting). As of April 22, 2019, the record date for the Annual Meeting, there were 40,588,004 outstanding shares of the Companys common stock. The Companys stockholders voted on the following matters, which are described in detail in the Companys Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission (SEC) on April 30, 2019: (i) to elect Anupam Dalal, Pravin Dugel and Steven Prelack as Class II directors of the Company to each serve for a three-year term, expiring at the Companys annual meeting of stockholders in 2022 and until their successors have been elected and qualified , subject to their earlier resignation or removal (Proposal 1) and (ii) to ratify the appointment of Ernst & Young, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019 (Proposal 2).
The Companys stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The Companys stockholders voted for Class II directors as follows:
Class II Director Nominee |
For |
Withhold |
Broker Non-Votes | |||
Anupam Dalal |
20,462,801 | 1,202,063 | 12,066,068 | |||
Pravin Dugel |
20,458,243 | 1,206,621 | 12,066,068 | |||
Steven Prelack |
20,465,288 | 1,199,576 | 12,066,068 |
The Companys stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:
For |
Against |
Abstain | ||
32,498,947 | 1,082,676 | 149,309 |
No other matters were submitted to or voted on by the Companys stockholders at the Annual Meeting.
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 19, 2019 | AERPIO PHARMACEUTICALS, INC. | |||||
By: | /s/ Stephen Hoffman | |||||
Stephen Hoffman Chief Executive Officer |